Article · 29 Aug 2026
Conference abstract
HIV DNA remaining not detectable two years after Tat Oyi vaccination in HIV infected volunteers under cART
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
A synthetic vaccine targeting the HIV Tat protein was tested on HIV infected volunteers under antiretroviral treatment (cART) at Marseille. BIOSANTECH is the sponsor of this monocentric clinical trial divided in a phase I/IIa and in a phase IIb. The protocol, based on the hypothesis that neutralizing antibodies against Tat may contribute to eliminate HIV infected cells, was authorized by the French drug administration (ANSM) on January 24th, 2013. Long term HIV infected volunteers (n=48) were randomized in four groups having at M0, M1 and M2 double blinded intradermal injections respectively with 0, 11, 33 or 99 μg of a synthetic protein called as Tat Oyi in a phosphate buffer complemented with NaCl (9 g/l) without adjuvant. The result of Phase I/IIa revealed that the Tat Oyi vaccine was safe and was statistically effective at lowering the extent of HIV RNA (Mann and Whitney test, p=0.07, 95% confidence interval) following a cART interruption from M5 to M6 (Loret et al., 2016). Follow up of volunteers showed that HIV DNA remains no longer detectable at M24 in those who got the vaccine (Figure 1). HIV DNA not detectable for a long period of time is never observed in HIV infected patients under cART. This is the first step toward HIV eradication reached by the Berlin patients in 2009. The second step is a decrease of antibodies against HIV (retro seroconversion) that the Berlin patient reached in 2012. A phase IIb will begin soon on volunteers who participated to phase I/IIa. The main outcome is that Tat Oyi vaccinated volunteers who are HIV DNA not detectable, with a rétroséroconversion, can stop cART and remain HIV RNA and HIV DNA not detectable. In that case, the Tat Oyi vaccine would allow HIV infected patient to reach a functional cure.
Keywords
Subjects
Vaccines & ImmunisationAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Vaccines & Vaccination.
Article · 29 Aug 2026
Advances in Adjuvant Development for Enhanced Vaccine Performance and Long-Term Immune Protection
Article · 20 Jun 2026
Herd Immunity and Its Role in Controlling Infectious Diseases
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Vaccines & Vaccination
- SubjectVaccines & Immunisation
- BylineArticles whose byline prints “Erwann Loret”